Last reviewed · How we verify
NCT07367529
A Phase Ib/II Clinical Trial to Evaluate the Efficacy and Safety of TQB6411 for Injection in Patients With Advanced Lung Cancer
Phase 1/Phase 2 trial testing TQB6411 for Injection in Advanced Lung Cancer in 465 participants. Currently enrolling.
1 December 2028
Quick facts
| Lead sponsor | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
|---|---|
| Phase | Phase 1/Phase 2 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 465 |
| Start date | 26 February 2026 |
| Primary completion | 1 December 2028 |
| Estimated completion | 1 December 2028 |
| Sites | 37 locations across China |
Drugs / interventions tested
- TQB6411 for Injection — full drug profile →
Conditions studied
- Advanced Lung Cancer — all drugs for Advanced Lung Cancer →
Sponsor
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. — full company profile →
Who can join
Adults 18 to 75, any sex, with Advanced Lung Cancer. Patients with the condition only — healthy volunteers not accepted.
What's being measured
Primary outcomes are the specific endpoints the trial is designed to prove or disprove.
-
Recommended Phase II Dosage for the Treatment (RP2D)
Time frame: Baseline up to 21 days
Recommended phase II dosage for the treatment of advanced Lung Cancer. -
Objective Response Rate (ORR)
Time frame: Baseline up to 6 mouths
Objective response rate for the treatment of advanced Lung Cancer.
Sponsor's own description
To evaluate the efficacy and safety of TQB6411 for Injection in subjects with advanced lung cancer
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07367529
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Advanced Lung Cancer
Currently open trials in the same condition.
- NCT07227623 — A Digital Health Intervention to Improve Physical Function and Wellness of Lung Cancer Survivors · NA · recruiting
- NCT06992583 — Targeted Anti-CEA CAR-T Immunotherapy for Advanced Lung Cancer · Phase 1 · recruiting
- NCT06945523 — Clinical Study on Chimeric Antigen Receptor T Lymphocyte (CAR-T) Targeting CEA for the Treatment of CEA - Positive Advan · Phase 1 · recruiting
- NCT06903117 — Anti-CEA CAR-T for Advanced CEA-Positive Lung Carcinoma · Phase 1 · recruiting
- NCT06928922 — Inhaled mRNA Tumor-associated Antigen Dry Powder Vaccine in Advanced Lung Cancer and Lung Metastasis of Solid Tumors. · EARLY_PHASE1 · recruiting
Other Chia Tai Tianqing Pharmaceutical Group Co., Ltd. trials
Trials by the same sponsor.
- NCT06990776 — A Clinical Trial to Evaluate the Efficacy and Safety of TQA3605 Tablets in Treatment-naive Chronic HBV-infected Subjects · Phase 2 · withdrawn
- NCT06851442 — Clinical Trial of Evaluating TQB3912 Tablets Combined With Fulvestrant Injection±TQB3616 Capsules for Locally Advanced o · Phase 1, PHASE2 · terminated
- NCT06711991 — A Clinical Trial of TQC3927 Powder for Inhalation in Chronic Obstructive Pulmonary Disease · Phase 1 · completed
- NCT06672276 — To Evaluate the Pharmacokinetics and Safety of TQD3606 for Injection in Subjects With Renal Insufficiency · Phase 1 · completed
- NCT06644417 — Clinical Study of TQA3605 Tablets Combined With Nucleoside (Acid) Analogs (NAs) Drugs Compared With NAs Drugs in the Tre · Phase 2 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07367529 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Last refreshed: 29 April 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07367529.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing